Pharma News
19 Apr 2026 to 25 Apr 2026
Apr 20, 2026
Is Bristol-Myers Squibb's (US0897961004) leadership in oncology robust?
Bristol-Myers Squibb's strong oncology portfolio, highlighted by blockbuster drug Opdivo, positions it well for U.S. investors despite concerns over pipeline sustainability and patent expirations. The company focuses on innovative treatments in oncology and immunology, with key products like Eliquis and Revlimid. Analysts maintain a positive outlook, emphasizing the importance of R&D and strategic partnerships for future growth.
Apr 20, 2026
Authorities in Gurgaon confiscated a fake weight loss drug valued at Rs 56 lakh from a taxi, with a primary suspect involved.
Authorities in Gurgaon have dismantled a counterfeit syndicate producing fake Mounjaro injections, a weight loss drug by Eli Lilly. Police seized spurious products worth over Rs 56 lakh from a cab, arresting Mujammil Khan and Avi Sharma, who allegedly manufactured the drugs at home. The operation highlights the rising illegal market for Mounjaro amid increased demand for weight loss treatments.
Apr 20, 2026
Is Novartis AG's pipeline of innovative medications robust enough to ensure long-term growth for its stock?
Novartis AG is focusing on breakthrough therapies like Kisqali and Pluvicto to navigate patent cliffs and enhance investor value. The company emphasizes R&D in oncology, immunology, and cardiovascular disease, while maintaining a strong portfolio with products like Entresto. Analysts view Novartis positively, highlighting its potential for growth amid industry challenges.
Apr 20, 2026
Bristol-Myers Squibb's stock: Does its cancer treatment pipeline have the potential to drive growth?
Bristol-Myers Squibb faces challenges from patent expirations but is positioned for growth with a strong pipeline of cancer therapies, including Opdivo and Breyanzi. Analysts maintain a positive outlook, emphasizing the company's immuno-oncology innovations and strategic partnerships. Risks include potential revenue declines from generics and competitive pressures. The stock remains attractive for U.S. investors seeking defensive growth.
Apr 19, 2026
Merck & Co., Inc. stock (US58933Y1055): Can Keytruda's leading position drive significant growth?
Merck & Co., Inc. continues to thrive in the competitive pharmaceutical landscape, driven by its oncology leader Keytruda. The company’s robust pipeline and focus on high-margin therapeutics position it well for U.S. investors. Analysts maintain positive views, citing sustained demand and growth potential, despite risks from patent expirations and regulatory challenges.
Apr 19, 2026
Aurobindo Pharma Ltd's shares: Can its leading position in generics drive growth?
Aurobindo Pharma, a leading Indian generic drug manufacturer, focuses on affordable generics, positioning itself as a key player in global pharma supply. With a robust pipeline and strategic initiatives, it aims to meet rising healthcare demands while offering U.S. and English-speaking investors indirect exposure to lower drug prices. However, regulatory risks and pricing pressures remain concerns.
Apr 19, 2026
Eli Lilly is reportedly in advanced negotiations to purchase Kelonia Therapeutics for more than $2 billion, according to the Wall Street Journal.
Eli Lilly is in advanced talks to acquire biotech firm Kelonia Therapeutics for over $2 billion, according to The Wall Street Journal. The deal, potentially finalized soon, aims to enhance Lilly's cancer portfolio, which includes therapies like Jaypirca and Verzenio, as Kelonia focuses on CAR-T cell therapies for cancer treatment.
Apr 19, 2026
Novo Nordisk A/S shares (DK0062498333): Can its leading position in obesity medications sustain...
Novo Nordisk A/S continues to lead in diabetes and obesity treatments with blockbuster drugs Ozempic and Wegovy, driving significant revenue growth. However, competition from Eli Lilly and pricing pressures pose challenges. Analysts maintain bullish ratings, citing strong market share and pipeline potential, while risks include supply shortages and regulatory hurdles. The stock remains a key consideration for U.S. investors.
Apr 19, 2026
Merck & Co., Inc. stock (US58933Y1055): Can Keytruda's leading position maintain its strength?
Merck & Co., Inc. faces challenges as its leading oncology drug, Keytruda, approaches patent expiration in 2028. While Keytruda generates over $20 billion annually, investors must assess Merck's pipeline and strategic acquisitions for future growth. Analysts maintain a positive outlook, but risks include potential revenue drops and competitive pressures. Upcoming data readouts and regulatory milestones will be crucial for Merck's trajectory.
